FacebookEmailPrint
FacebookEmail

    Overview

    The development of accurate and reproducible immune monitoring assays is essential to determine the immune responses in patients receiving novel immune therapies and ultimately transitioning these therapies from the clinical trial phase to standard of care. The goal of the Translational Immunology Section (TIS) is to develop cutting-edge immune monitoring technology that will be made available to all NIAMS investigators.

    The Translational Immunology Section supports NIAMS scientists with:

    • Consultative advice and in-depth instructions in a variety of immunologic methods to facilitate their interpretation of immunoassays most relevant to a particular clinical trial or to study a particular patient.
    • State-of-the-art immunoassays such as high parameters, multicolor flow cytometry, Luminex, and NanoString transcriptomic analysis enabling NIAMS clinicians to monitor the immune responses of their patients.
    • Analysis of a reference population to define baseline responses, ensuring quality control checks that will validate the reproducibility of these results.
    • Analysis of the mechanism of action of JAK inhibitors on various immune cell populations.

    Scientific Advances

    The Transcription Factor STAT4 Controls the Fate of Cytotoxic Innate Lymphocytes

    In the Lab with NIAMS

    Learn more about the NIAMS Translational Immunology Section, a Core Facility in the institute’s Intramural Research Program. This facility uses genomic approaches to understand the underlying factors of human diseases.

    Core Research Facilities

    Labs at the NIAMS are supported by the following state-of-the-art facilities and services:

    Scientific Publications

    Selected Recent Publications

    Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story.

    Bonelli M, Kerschbaumer A, Kastrati K, Ghoreschi K, Gadina M, Heinz LX, Smolen JS, Aletaha D, O'Shea J, Laurence A
    Ann Rheum Dis.
    2024 Jan 11;
    83(2).
    doi: 10.1136/ard-2023-223850
    PMID: 37923366

    Variant STAT4 and Response to Ruxolitinib in an Autoinflammatory Syndrome.

    Baghdassarian H, Blackstone SA, Clay OS, Philips R, Matthiasardottir B, Nehrebecky M, Hua VK, McVicar R, Liu Y, Tucker SM, Randazzo D, Deuitch N, Rosenzweig S, Mark A, Sasik R, Fisch KM, Pimpale Chavan P, Eren E, Watts NR, Ma CA, Gadina M, Schwartz DM, Sanyal A, Werner G, Murdock DR, Horita N, Chowdhury S, Dimmock D, Jepsen K, Remmers EF, Goldbach-Mansky R, Gahl WA, O'Shea JJ, Milner JD, Lewis NE, Chang J, Kastner DL, Torok K, Oda H, Putnam CD, Broderick L
    N Engl J Med.
    2023 Jun 15;
    388(24).
    doi: 10.1056/NEJMoa2202318
    PMID: 37256972

    Protein kinases: drug targets for immunological disorders.

    Castelo-Soccio L, Kim H, Gadina M, Schwartzberg PL, Laurence A, O'Shea JJ
    Nat Rev Immunol.
    2023 Dec;
    23(12).
    doi: 10.1038/s41577-023-00877-7
    PMID: 37188939

    Cell Viability Multiplexing: Quantification of Cellular Viability by Barcode Flow Cytometry and Computational Analysis.

    Giudice V, Fonseca V, Selleri C, Gadina M
    Methods Mol Biol.
    2023;
    2644().
    doi: 10.1007/978-1-0716-3052-5_7
    PMID: 37142918

    PDIA3 epitope-driven immune autoreactivity contributes to hepatic damage in type 2 diabetes.

    Clement CC, Osan J, Buque A, Nanaware PP, Chang YC, Perino G, Shetty M, Yamazaki T, Tsai WL, Urbanska AM, Calvo-Calle JM, Ramsamooj S, Ramsamooj S, Vergani D, Mieli-Vergani G, Terziroli Beretta-Piccoli B, Gadina M, Montagna C, Goncalves MD, Sallusto F, Galluzzi L, Soni RK, Stern LJ, Santambrogio L
    Sci Immunol.
    2022 Aug 12;
    7(74).
    doi: 10.1126/sciimmunol.abl3795
    PMID: 35984892

    The JAK-STAT pathway at 30: Much learned, much more to do.

    Philips RL, Wang Y, Cheon H, Kanno Y, Gadina M, Sartorelli V, Horvath CM, Darnell JE Jr, Stark GR, O'Shea JJ
    Cell.
    2022 Oct 13;
    185(21).
    doi: 10.1016/j.cell.2022.09.023
    PMID: 36240739

    Affecting the effectors: JAK inhibitors modulation of immune cell numbers and functions in patients with rheumatoid arthritis.

    Garufi C, Maclean M, Gadina M, Spinelli FR
    Expert Rev Clin Immunol.
    2022 Mar;
    18(3).
    doi: 10.1080/1744666X.2022.2042254
    PMID: 35168456

    Jakinibs of All Trades: Inhibiting Cytokine Signaling in Immune-Mediated Pathologies.

    Alexander M, Luo Y, Raimondi G, O'Shea JJ, Gadina M
    Pharmaceuticals (Basel).
    2021 Dec 30;
    15(1).
    doi: 10.3390/ph15010048
    PMID: 35056105

    Granzyme A and CD160 expression delineates ILC1 with graded functions in the mouse liver.

    Di Censo C, Marotel M, Mattiola I, Müller L, Scarno G, Pietropaolo G, Peruzzi G, Laffranchi M, Mazej J, Hasim MS, Asif S, Russo E, Tomaipitinca L, Stabile H, Lee SH, Vian L, Gadina M, Gismondi A, Shih HY, Mikami Y, Capuano C, Bernardini G, Bonelli M, Sozzani S, Diefenbach A, Ardolino M, Santoni A, Sciumè G
    Eur J Immunol.
    2021 Nov;
    51(11).
    doi: 10.1002/eji.202149209
    PMID: 34347289

    3-hydroxy-L-kynurenamine is an immunomodulatory biogenic amine.

    Clement CC, D'Alessandro A, Thangaswamy S, Chalmers S, Furtado R, Spada S, Mondanelli G, Ianni F, Gehrke S, Gargaro M, Manni G, Cara LCL, Runge P, Tsai WL, Karaman S, Arasa J, Fernandez-Rodriguez R, Beck A, Macchiarulo A, Gadina M, Halin C, Fallarino F, Skobe M, Veldhoen M, Moretti S, Formenti S, Demaria S, Soni RK, Galarini R, Sardella R, Lauvau G, Putterman C, Alitalo K, Grohmann U, Santambrogio L
    Nat Commun.
    2021 Jul 21;
    12(1).
    doi: 10.1038/s41467-021-24785-3
    PMID: 34290243

    A Decade of JAK Inhibitors: What Have We Learned and What May Be the Future?

    Liu C, Kieltyka J, Fleischmann R, Gadina M, O'Shea JJ
    Arthritis Rheumatol.
    2021 Dec;
    73(12).
    doi: 10.1002/art.41906
    PMID: 34180156

    Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus.

    Hasni SA, Gupta S, Davis M, Poncio E, Temesgen-Oyelakin Y, Carlucci PM, Wang X, Naqi M, Playford MP, Goel RR, Li X, Biehl AJ, Ochoa-Navas I, Manna Z, Shi Y, Thomas D, Chen J, Biancotto A, Apps R, Cheung F, Kotliarov Y, Babyak AL, Zhou H, Shi R, Stagliano K, Tsai WL, Vian L, Gazaniga N, Giudice V, Lu S, Brooks SR, MacKay M, Gregersen P, Mehta NN, Remaley AT, Diamond B, O'Shea JJ, Gadina M, Kaplan MJ
    Nat Commun.
    2021 Jun 7;
    12(1).
    doi: 10.1038/s41467-021-23361-z
    PMID: 34099646

    JAK1: Number one in the family; number one in inflammation?

    Spinelli FR, Colbert RA, Gadina M
    Rheumatology (Oxford).
    2021 May 5;
    60(Suppl 2).
    doi: 10.1093/rheumatology/keab024
    PMID: 33950229

    Pleiotropic consequences of metabolic stress for the major histocompatibility complex class II molecule antigen processing and presentation machinery.

    Clement CC, Nanaware PP, Yamazaki T, Negroni MP, Ramesh K, Morozova K, Thangaswamy S, Graves A, Kim HJ, Li TW, Vigano' M, Soni RK, Gadina M, Tse HY, Galluzzi L, Roche PA, Denzin LK, Stern LJ, Santambrogio L
    Immunity.
    2021 Apr 13;
    54(4).
    doi: 10.1016/j.immuni.2021.02.019
    PMID: 33725478

    Janus kinase (JAK) inhibition with baricitinib in refractory juvenile dermatomyositis.

    Kim H, Dill S, O'Brien M, Vian L, Li X, Manukyan M, Jain M, Adeojo LW, George J, Perez M, Grom AA, Sutter M, Feldman BM, Yao L, Millwood M, Brundidge A, Pichard DC, Cowen EW, Shi Y, Lu S, Tsai WL, Gadina M, Rider LG, Colbert RA
    Ann Rheum Dis.
    2021 Mar;
    80(3).
    doi: 10.1136/annrheumdis-2020-218690
    PMID: 32843325

    Key Publications

    JAK inhibitors: Ten years after.

    Spinelli FR, Meylan F, O'Shea JJ, Gadina M
    Eur J Immunol.
    2021 Apr 30;
    doi: 10.1002/eji.202048922
    PMID: 33930196

    Somatic Mutations in UBA1 and Severe Adult-Onset Autoinflammatory Disease.

    Beck DB, Ferrada MA, Sikora KA, Ombrello AK, Collins JC, Pei W, Balanda N, Ross DL, Ospina Cardona D, Wu Z, Patel B, Manthiram K, Groarke EM, Gutierrez-Rodrigues F, Hoffmann P, Rosenzweig S, Nakabo S, Dillon LW, Hourigan CS, Tsai WL, Gupta S, Carmona-Rivera C, Asmar AJ, Xu L, Oda H, Goodspeed W, Barron KS, Nehrebecky M, Jones A, Laird RS, Deuitch N, Rowczenio D, Rominger E, Wells KV, Lee CR, Wang W, Trick M, Mullikin J, Wigerblad G, Brooks S, Dell'Orso S, Deng Z, Chae JJ, Dulau-Florea A, Malicdan MCV, Novacic D, Colbert RA, Kaplan MJ, Gadina M, Savic S, Lachmann HJ, Abu-Asab M, Solomon BD, Retterer K, Gahl WA, Burgess SM, Aksentijevich I, Young NS, Calvo KR, Werner A, Kastner DL, Grayson PC
    N Engl J Med.
    2020 Dec 31;
    383(27).
    doi: 10.1056/NEJMoa2026834
    PMID: 33108101

    HiJAKing SARS-CoV-2? The potential role of JAK inhibitors in the management of COVID-19.

    Spinelli FR, Conti F, Gadina M
    Sci Immunol.
    2020 May 8;
    5(47).
    pii: eabc5367. doi: 10.1126/sciimmunol.abc5367
    PMID: 32385052

    JAK Inhibition Differentially Affects NK Cell and ILC1 Homeostasis.

    Vian L, Le MT, Gazaniga N, Kieltyka J, Liu C, Pietropaolo G, Dell'Orso S, Brooks SR, Furumoto Y, Thomas CJ, O'Shea JJ, Sciumè G, Gadina M
    Front Immunol.
    2019;
    10().
    doi: 10.3389/fimmu.2019.02972
    PMID: 31921209

    High throughput pSTAT signaling profiling by fluorescent cell barcoding and computational analysis.

    Tsai WL, Vian L, Giudice V, Kieltyka J, Liu C, Fonseca V, Gazaniga N, Gao S, Kajigaya S, Young NS, Biancotto A, Gadina M
    J Immunol Methods.
    2020 Feb;
    477().
    doi: 10.1016/j.jim.2019.112667
    PMID: 31726053

    News & Highlights

    no-news-results
    FacebookEmailPrint
    FacebookEmail
    Last Updated: February 2024
    Back to Top